PMID- 29705620
OWN - NLM
STAT- MEDLINE
DCOM- 20190207
LR  - 20220409
IS  - 1522-9629 (Electronic)
IS  - 1094-5539 (Linking)
VI  - 51
DP  - 2018 Aug
TI  - Impact of doxofylline in COPD: A pairwise meta-analysis.
PG  - 1-9
LID - S1094-5539(18)30094-4 [pii]
LID - 10.1016/j.pupt.2018.04.010 [doi]
AB  - Doxofylline is an effective bronchodilator for relieving airway obstruction in 
      patients with asthma or chronic obstructive pulmonary disease (COPD), and 
      displays a better safety profile with respect to theophylline. Herein, we 
      performed a pairwise meta-analysis of the currently available data to provide 
      consistent and homogeneous findings on the impact of this xanthine in COPD 
      patients. Results obtained from 820 patients were selected from 20 clinical 
      trials. Meta-regression was performed to examine the source of heterogeneity 
      between-studies and identify potential confounder covariates. The quality of the 
      evidence was assessed by the GRADE system. Doxofylline induced a significant 
      (P < 0.001) increase in forced expiratory volume in 1 s (FEV(1)) of 8.20% (95%CI 
      4.00-12.41; I(2) 93%) and 317 ml (95%CI 19-439; I(2) 87%) compared with baseline. 
      The total administered dose of doxofylline significantly (P < 0.001) interacted 
      with the size of the effect estimates detected for FEV(1). Doxofylline induced a 
      significant (P < 0.001), although moderate, increase in adverse events (AEs) 
      frequency (proportion 0.03, 95%CI 0.02-0.04; I(2) 88%), but only epigastralgia, 
      nausea, dyspepsia and headache were statistically significant (P < 0.05). The 
      GRADE analysis indicated high quality of evidence (++++) for the impact of 
      doxofylline on FEV(1), and moderate quality of evidence (+++) for the safety 
      profile in COPD patients. Doxofylline is an effective and safe medicine when 
      administered to patients with COPD and can be considered as an alternative to 
      theophylline.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Cazzola, Mario
AU  - Cazzola M
AD  - Unit of Respiratory Medicine, Department of Experimental Medicine and Surgery, 
      University of Rome "Tor Vergata", Rome, Italy.
FAU - Calzetta, Luigino
AU  - Calzetta L
AD  - Unit of Respiratory Medicine, Department of Experimental Medicine and Surgery, 
      University of Rome "Tor Vergata", Rome, Italy. Electronic address: 
      luigino.calzetta@uniroma2.it.
FAU - Rogliani, Paola
AU  - Rogliani P
AD  - Unit of Respiratory Medicine, Department of Experimental Medicine and Surgery, 
      University of Rome "Tor Vergata", Rome, Italy.
FAU - Page, Clive
AU  - Page C
AD  - Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, 
      King's College London, London, UK.
FAU - Matera, Maria Gabriella
AU  - Matera MG
AD  - Unit of Pharmacology, Department of Experimental Medicine, University of Campania 
      "Luigi Vanvitelli", Naples, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180426
PL  - England
TA  - Pulm Pharmacol Ther
JT  - Pulmonary pharmacology & therapeutics
JID - 9715279
RN  - 0 (Bronchodilator Agents)
RN  - C137DTR5RG (Theophylline)
RN  - MPM23GMO7Z (doxofylline)
SB  - IM
MH  - Bronchodilator Agents/*administration & dosage/adverse effects/pharmacology
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology
MH  - Theophylline/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Chronic obstructive pulmonary disease
OT  - Doxofylline
OT  - Lung function
OT  - Pairwise meta-analysis
OT  - Safety
EDAT- 2018/05/01 06:00
MHDA- 2019/02/08 06:00
CRDT- 2018/04/30 06:00
PHST- 2018/04/16 00:00 [received]
PHST- 2018/04/24 00:00 [accepted]
PHST- 2018/05/01 06:00 [pubmed]
PHST- 2019/02/08 06:00 [medline]
PHST- 2018/04/30 06:00 [entrez]
AID - S1094-5539(18)30094-4 [pii]
AID - 10.1016/j.pupt.2018.04.010 [doi]
PST - ppublish
SO  - Pulm Pharmacol Ther. 2018 Aug;51:1-9. doi: 10.1016/j.pupt.2018.04.010. Epub 2018 
      Apr 26.